<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-562" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>HLA-B*57:01 Testing</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gilani</surname>
            <given-names>Brian</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zubair</surname>
            <given-names>Muhammad</given-names>
          </name>
          <aff>Indus Hospital &#x00026; Health Network</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brian Gilani declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Zubair declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-562.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>HIV targets the body&#x02019;s immune system&#x02014;specifically CD4&#x000a0;T cells. The virus is transmitted through bodily fluids but can remain undetected in its host for years, causing a diverse array of complications. During the progression of HIV infection, a patient&#x02019;s CD4 lymphocyte count will decrease. Individuals with HIV who&#x000a0;do not receive treatment can develop&#x000a0;AIDS once their CD4 lymphocyte count decreases; these patients are highly susceptible to opportunistic infection. Patients that develop AIDS and remain untreated have a 1&#x000a0;to 2 years prognosis of survival.<xref ref-type="bibr" rid="article-562.r1">[1]</xref></p>
        <p>Due to the loci of infection, managing the virus uses a multifaceted approach. The core of HIV treatment is highly active antiretroviral therapy (HAART). In most patients, HAART includes 2 nucleoside reverse transcriptase inhibitors (NRTIs) and an integrase strand transfer inhibitor (InSTI).<xref ref-type="bibr" rid="article-562.r2">[2]</xref>&#x000a0;These regimens seek to interrupt viral replication and slow disease progression. Abacavir is an NRTI.<xref ref-type="bibr" rid="article-562.r3">[3]</xref></p>
        <p>Abacavir causes a hypersensitive response in 5% to 8% of patients treated. Cytotoxic&#x000a0;T cells mediate the hypersensitivity reaction to abacavir. Hypersensitivity reactions (HSR) can occur within the first 6 weeks of treatment if genetic prescreening is not conducted. If the drug is continued despite worsening symptoms, the severity of the HSR can escalate over time. Symptoms of an HSR typically include at least 2 of the following: fever, rash, fatigue, cough, difficulty breathing, and gastrointestinal issues such as nausea, vomiting, or abdominal pain.<xref ref-type="bibr" rid="article-562.r4">[4]</xref><xref ref-type="bibr" rid="article-562.r5">[5]</xref></p>
        <p>If an HSR is suspected, abacavir should be discontinued immediately. Should the symptoms of a clinically diagnosed HSR improve after stopping abacavir, it is crucial to avoid reintroducing the drug, as this can lead to immediate and potentially life-threatening reactions, including anaphylaxis and death.<xref ref-type="bibr" rid="article-562.r6">[6]</xref> The signs and symptoms of abacavir hypersensitivity are nonspecific&#x000a0;and may be confused with other conditions frequently encountered in HIV-positive patients, such as infections, immune restoration disease, and hypersensitivity reactions to other medications.<xref ref-type="bibr" rid="article-562.r7">[7]</xref> Therefore, understanding the mechanism and predictive power of the&#x000a0;major histocompatibility complex, class I, B 57:01 (HLA-B*57:01) allele concerning hypersensitive reactions is critical in shaping the best clinical practices.<xref ref-type="bibr" rid="article-562.r8">[8]</xref></p>
      </sec>
      <sec id="article-562.s2" sec-type="Specimen Collection">
        <title>Specimen Collection</title>
        <p>Specimen&#x000a0;collection&#x000a0;uses whole blood and&#x000a0;buccal mucosa swabs.&#x000a0;The volume of the sample/specimen should be&#x000a0;7 mL in a whole blood&#x02013;lavender-top (ethylenediaminetetraacetic acid; EDTA) tube&#x000a0;and 4 buccal swabs in a sealed buccal swab envelope kit.&#x000a0;The EDTA prevents clotting and preserves the cellular components essential for accurate testing.<xref ref-type="bibr" rid="article-562.r9">[9]</xref> After collection, the tube should be gently inverted several times to ensure proper mixing of the blood with the EDTA. The specimen must be stored at room temperature and processed as soon as possible to prevent degradation of the cells.<xref ref-type="bibr" rid="article-562.r10">[10]</xref></p>
        <p>Care must be taken during the blood collection to prevent hemolysis, which can occur if the blood is drawn too forcefully or if the collection tube is shaken vigorously. Hemolysis can release intracellular components that may interfere with the test results.<xref ref-type="bibr" rid="article-562.r11">[11]</xref>&#x000a0;When collecting buccal swabs, avoiding touching the swab tip with fingers or any nonsterile surfaces is essential to reduce the risk of contamination, which can compromise the sample's integrity.<xref ref-type="bibr" rid="article-562.r12">[12]</xref></p>
        <p>Clinicians should ensure buccal swabs are completely dry before sealing them in an envelope. Failing to do so can result in the degradation of cellular material, potentially leading to inaccurate test results.&#x000a0;Patients should not eat, drink, smoke, or chew gum for 30 minutes before specimen collection.<xref ref-type="bibr" rid="article-562.r13">[13]</xref></p>
      </sec>
      <sec id="article-562.s3" sec-type="Procedures">
        <title>Procedures</title>
        <p>After establishing a link between the HLA-B*57:01 allele and abacavir, monitoring for the allele and hypersensitive response became routine in antiretroviral therapy, accomplished through genetic screening. Testing for HLA-B*57:01 most commonly uses a blood or saliva sample for sequence-based genotyping using a polymerase chain reaction.<xref ref-type="bibr" rid="article-562.r8">[8]</xref>&#x000a0;Following these tests, the clinician will know if the patient is positive for the HLA-B*57:01 allele and be able to&#x000a0;alter the treatment accordingly.&#x000a0;</p>
        <p>For patients with the HLA-B*57:01 allele, safely and conclusively diagnosing hypersensitivity is another necessary step in determining drug efficacy. To confirm hypersensitivity, an epicutaneous patch test is administered after the patient has had exposure to abacavir. A skin patch must occur after the immune system has been exposed to the drug's effects because a rechallenge will produce a measurable response. Skin patch testing uses concentrations of 1% and 10% abacavir in petrolatum along with a control without abacavir. These patches can then be read 24 and 48 hours after application. A positive hypersensitive response is a palpable cutaneous response on the skin surface where abacavir was introduced.<xref ref-type="bibr" rid="article-562.r14">[14]</xref><xref ref-type="bibr" rid="article-562.r15">[15]</xref><xref ref-type="bibr" rid="article-562.r16">[16]</xref></p>
        <p>Implementing comprehensive quality assurance processes for HLA-B*57:01 testing is essential for accurately identifying patients at risk for abacavir hypersensitivity.<xref ref-type="bibr" rid="article-562.r17">[17]</xref> By focusing on routine equipment calibration, continuous staff training, participation in proficiency testing programs, adherence to standard operating procedures, and diligent documentation, laboratories can enhance the reliability of their testing results. These quality control measures improve patient safety and contribute to the overall quality of care in pharmacogenetic testing.<xref ref-type="bibr" rid="article-562.r18">[18]</xref><xref ref-type="bibr" rid="article-562.r19">[19]</xref></p>
        <p>Participation in regular external quality assessment surveys allows labs to monitor their performance over time. External quality assessment programs distribute blinded samples to participating laboratories for HLA-B*57:01 typing. This allows for an objective assessment of each lab's performance in accurately detecting the presence or absence of the allele. Any deviations from expected results can prompt investigations into potential sources of error and implementation of corrective actions.<xref ref-type="bibr" rid="article-562.r20">[20]</xref><xref ref-type="bibr" rid="article-562.r21">[21]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-562.s4" sec-type="Indications">
        <title>Indications</title>
        <p>Patients with HIV should be screened for HLA-B*57:01 when preparing an antiretroviral therapy drug regimen, especially when considering abacavir. Even if previously tolerated, screening should happen before restarting abacavir therapy if the HLA-B*57:01 status is unknown.&#x000a0;Implementing HLA-B*57:01 screening in clinical practice has been shown to reduce the incidence of abacavir hypersensitivity reactions from 1.3% to 0.2% over several years, demonstrating the clinical benefit of genetic screening before treatment initiation.<xref ref-type="bibr" rid="article-562.r17">[17]</xref><xref ref-type="bibr" rid="article-562.r8">[8]</xref></p>
        <p>In addition to its link with abacavir hypersensitivity reactions, HLA-B*57:01 has also been associated with liver injury caused by flucloxacillin. While individuals&#x000a0;with the HLA-B*57:01&#x000a0;allele have a greater than 40-fold increased risk of liver injury compared to those who without the allele, flucloxacillin-induced hepatotoxicity remains very rare, occurring in fewer than 1 in 5000 cases. This incidence is significantly lower than that of abacavir hypersensitivity reactions. Therefore, routine screening for HLA-B*57:01 to assess the risk of flucloxacillin-induced liver injury is not commonly performed.<xref ref-type="bibr" rid="article-562.r22">[22]</xref><xref ref-type="bibr" rid="article-562.r23">[23]</xref></p>
      </sec>
      <sec id="article-562.s5" sec-type="Normal and Critical Findings">
        <title>Normal and Critical Findings</title>
        <p>Screening for the presence of the HLA-B*57:01 allele should always be conducted to avoid possible morbidity from allergic reactions. The genotype results for the HLA-B*57:01 allele can be classified as either positive or negative, with no intermediate phenotypes due to the codominant expression of HLA genes. A positive result indicates that the patient has at least 1 copy allele; patients may be heterozygous or homozygous.<xref ref-type="bibr" rid="article-562.r24">[24]</xref></p>
        <p>In patients with a positive result, abacavir is contraindicated. Due to the implications of positive results for the HLA-B*57:01 allele, using abacavir in treatment is avoided. Instead, clinicians should substitute a different NRTI in the therapeutic regimen. Conversely, a negative result signifies that the patient does not possess the HLA-B*57:01 allele. If the patient is negative for the allele, clinicians can safely resume abacavir as a component of the patient's regimen.<xref ref-type="bibr" rid="article-562.r8">[8]</xref></p>
        <p>However, clinicians should note that a negative result does not eliminate the risk of developing hypersensitivity reactions to abacavir. Therefore, all patients should be monitored closely, following standard medical practices. In rare cases where HLA-B*57:01 testing is not available due to geographically low prevalence of the allele, clinicians may prescribe abacavir under close observation for the first 6 weeks, as the median onset time of HSR is typically 1 to 2 weeks.<xref ref-type="bibr" rid="article-562.r25">[25]</xref></p>
      </sec>
      <sec id="article-562.s6" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>In studies of abacavir hypersensitivity reaction or AHR, researchers found that a significant portion of hypersensitive diagnoses were false positives using epicutaneous patch testing. HLA-B*57:01 screening has shown to have a 100% negative predictive value.<xref ref-type="bibr" rid="article-562.r26">[26]</xref>&#x000a0;Interestingly, although all patients who&#x000a0;develop hypersensitivity have the HLA-B*57:01 allele, not all individuals with that genotype develop hypersensitivity. Mouse models have supported the hypothesis that CD4 T cells play a role in building tolerance for the altered antigen-presenting complex through cytotoxic lymphocyte-driven hypersensitive response.<xref ref-type="bibr" rid="article-562.r27">[27]</xref><xref ref-type="bibr" rid="article-562.r28">[28]</xref></p>
        <p>Clinicians must use patch testing to confirm the diagnosis of hypersensitivity in patients. In blind comparative trial regimens, 2% to 7% of patients were diagnosed with hypersensitivity without receiving abacavir.<xref ref-type="bibr" rid="article-562.r17">[17]</xref>&#x000a0;This discrepancy in true positive hypersensitivity recognition is due to the symptoms of hypersensitivity being nonspecific and difficult to distinguish from other ailments that could accompany the introduction of a new drug regimen.</p>
      </sec>
      <sec id="article-562.s7" sec-type="Complications">
        <title>Complications</title>
        <p>Hypersensitivity can manifest as a variety of symptoms. The most common AHR symptoms include fever, chills, rash, gastrointestinal, and respiratory symptoms. Patch testing is often used to confirm hypersensitivity and will cause a palpable cutaneous response on the skin.<xref ref-type="bibr" rid="article-562.r29">[29]</xref></p>
      </sec>
      <sec id="article-562.s8" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>As a&#x000a0;NRTI, abacavir competes with deoxynucleotides in host cells to prevent the creation of double-stranded viral DNA, thereby limiting HIV replication.<xref ref-type="bibr" rid="article-562.r30">[30]</xref>&#x000a0;Hypersensitivity can arise when individuals with antigen-presenting complexes linked to HLA-B*57:01 perform direct noncovalent bonding with abacavir.&#x000a0;Once bonded, the surface complex is altered and is then recognized as foreign by cytotoxic lymphocytes. This interaction results in the release of inflammatory cytokines that facilitate the hypersensitive response.<xref ref-type="bibr" rid="article-562.r14">[14]</xref>&#x000a0;Although it is primarily the parent drug that triggers hypersensitivity, it is hypothesized that abacavir metabolites may contribute to the immune response by generating altered peptides. These peptides might be presented on HLA molecules, potentially amplifying the immune response in some cases, but this is not considered the main pathway.<xref ref-type="bibr" rid="article-562.r25">[25]</xref><xref ref-type="bibr" rid="article-562.r31">[31]</xref></p>
        <p>Due to the severity of AHR, clinicians should conduct screenings for the HLA-B*57:01 allele to avoid a hypersensitive response in patients predisposed to this outcome. Clinicians must consider the patient&#x02019;s HLA-B*57:01 status when selecting a regimen. The recommendation is that patients receive an alternative NRTI to abacavir if they have the HLA-B*57:01 allele to avoid the possibility of a hypersensitive response.</p>
        <p>Since rechallenging the immune system after a hypersensitive response can produce extreme and life-threatening symptoms, the use of abacavir in patients who may have had an allergic reaction previously should be cautiously considered. Skin patch testing can also be a consideration in these cases since it is used exclusively in patients who have already taken abacavir and serves as a localized challenge instead of a systematic reintroduction. If clinicians observe these protocols and recommendations, clinicians and patients can make an informed selection of the components of their antiretroviral therapy. For most, abacavir is very effective in concert with an additional NRTI and an InSTI, but for a small percentage of genetically predisposed individuals, abacavir can result in a harmful hypersensitive reaction.</p>
      </sec>
      <sec id="article-562.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=562&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=562">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/562/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=562">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-562.s10">
        <title>References</title>
        <ref id="article-562.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Abdool Karim</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.</article-title>
            <source>Lancet</source>
            <year>2006</year>
            <month>Aug</month>
            <day>05</day>
            <volume>368</volume>
            <issue>9534</issue>
            <fpage>489</fpage>
            <page-range>489-504</page-range>
            <pub-id pub-id-type="pmid">16890836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000fc;nthard</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>del Rio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eron</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Gallant</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Hoy</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Mugavero</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sax</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Landovitz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Volberding</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.</article-title>
            <source>JAMA</source>
            <year>2016</year>
            <month>Jul</month>
            <day>12</day>
            <volume>316</volume>
            <issue>2</issue>
            <fpage>191</fpage>
            <page-range>191-210</page-range>
            <pub-id pub-id-type="pmid">27404187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Fernandez</surname>
                <given-names>JVB</given-names>
              </name>
              <name>
                <surname>Munir</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Abacavir</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">30725802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mounzer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fusco</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Brunet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Henegar</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Vannappagari</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Stainsby</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Shaefer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Ragone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fusco</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA<sup>&#x000ae;</sup> observational database: a cohort study.</article-title>
            <source>AIDS Res Ther</source>
            <year>2019</year>
            <month>Jan</month>
            <day>16</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">30651100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stainsby</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Perger</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Vannappagari</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mounzer</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Henegar</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Oyee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Urbaityte</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Pakes</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Shaefer</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.</article-title>
            <source>Pharmacotherapy</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-54</page-range>
            <pub-id pub-id-type="pmid">30414209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shapiro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>A near-fatal hypersensitivity reaction to abacavir: case report and literature review.</article-title>
            <source>AIDS Read</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>222</fpage>
            <page-range>222-6</page-range>
            <pub-id pub-id-type="pmid">11392679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carolino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pi&#x000f1;eiro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sarmento</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cernadas</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of abacavir-associated hypersensitivity syndrome and HLA-B*5701 allele in a Portuguese HIV-positive population.</article-title>
            <source>Porto Biomed J</source>
            <year>2017</year>
            <season>Mar-Apr</season>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>59</fpage>
            <page-range>59-62</page-range>
            <pub-id pub-id-type="pmid">32258586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>HLA-B*5701 testing to predict abacavir hypersensitivity.</article-title>
            <source>PLoS Curr</source>
            <year>2010</year>
            <month>Dec</month>
            <day>07</day>
            <volume>2</volume>
            <fpage>RRN1203</fpage>
            <pub-id pub-id-type="pmid">21151380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Banfi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Salvagno</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Lippi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The role of ethylenediamine tetraacetic acid (EDTA) as in vitro anticoagulant for diagnostic purposes.</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2007</year>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>565</fpage>
            <page-range>565-76</page-range>
            <pub-id pub-id-type="pmid">17484616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bayot</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Tadi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Laboratory Tube Collection</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">32310451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wan Azman</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Omar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koon</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Tuan Ismail</surname>
                <given-names>TS</given-names>
              </name>
            </person-group>
            <article-title>Hemolyzed Specimens: Major Challenge for Identifying and Rejecting Specimens in Clinical Laboratories.</article-title>
            <source>Oman Med J</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>94</fpage>
            <page-range>94-98</page-range>
            <pub-id pub-id-type="pmid">30918601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McMichael</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>O'Callaghan</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Goldwater</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Dekker</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Haan</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>MacLennan</surname>
                <given-names>AH</given-names>
              </name>
              <collab>South Australian Cerebral Palsy Research Group</collab>
            </person-group>
            <article-title>DNA from buccal swabs suitable for high-throughput SNP multiplex analysis.</article-title>
            <source>J Biomol Tech</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>232</fpage>
            <page-range>232-5</page-range>
            <pub-id pub-id-type="pmid">19949693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Livy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lye</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jagdish</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Hanis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sharmila</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ler</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Pramod</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of quality of DNA extracted from buccal swabs for microarray based genotyping.</article-title>
            <source>Indian J Clin Biochem</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-33</page-range>
            <pub-id pub-id-type="pmid">23277709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Illing</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Vivian</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Dudek</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Kostenko</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bharadwaj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miles</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kjer-Nielsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gras</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Burrows</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Purcell</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Rossjohn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McCluskey</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.</article-title>
            <source>Nature</source>
            <year>2012</year>
            <month>Jun</month>
            <day>28</day>
            <volume>486</volume>
            <issue>7404</issue>
            <fpage>554</fpage>
            <page-range>554-8</page-range>
            <pub-id pub-id-type="pmid">22722860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phillips</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Kaul</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shahabi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Knowles</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mallal</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Shear</surname>
                <given-names>NH</given-names>
              </name>
            </person-group>
            <article-title>Clinical and immunogenetic correlates of abacavir hypersensitivity.</article-title>
            <source>AIDS</source>
            <year>2005</year>
            <month>Jun</month>
            <day>10</day>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>979</fpage>
            <page-range>979-81</page-range>
            <pub-id pub-id-type="pmid">15905681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shear</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Milpied</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bruynzeel</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>A review of drug patch testing and implications for HIV clinicians.</article-title>
            <source>AIDS</source>
            <year>2008</year>
            <month>May</month>
            <day>31</day>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>999</fpage>
            <page-range>999-1007</page-range>
            <pub-id pub-id-type="pmid">18520343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mallal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carosi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Molina</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Workman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tomazic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>J&#x000e4;gel-Guedes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rugina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kozyrev</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cid</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Hay</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fitch</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Thorborn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Benbow</surname>
                <given-names>A</given-names>
              </name>
              <collab>PREDICT-1 Study Team</collab>
            </person-group>
            <article-title>HLA-B*5701 screening for hypersensitivity to abacavir.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>Feb</month>
            <day>07</day>
            <volume>358</volume>
            <issue>6</issue>
            <fpage>568</fpage>
            <page-range>568-79</page-range>
            <pub-id pub-id-type="pmid">18256392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tayeh</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Gaedigk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goetz</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Lyon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McMillin</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Rentas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shinawi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>SA</given-names>
              </name>
              <collab>ACMG Laboratory Quality Assurance Committee. Electronic address: documents@acmg.net</collab>
            </person-group>
            <article-title>Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG).</article-title>
            <source>Genet Med</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>759</fpage>
            <page-range>759-768</page-range>
            <pub-id pub-id-type="pmid">35177334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Quality control materials for pharmacogenomic testing in the clinic.</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2017</year>
            <month>Jun</month>
            <day>27</day>
            <volume>55</volume>
            <issue>7</issue>
            <fpage>926</fpage>
            <page-range>926-933</page-range>
            <pub-id pub-id-type="pmid">27845879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laudus</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nijs</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nauwelaers</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dequeker</surname>
                <given-names>EMC</given-names>
              </name>
            </person-group>
            <article-title>The Significance of External Quality Assessment Schemes for Molecular Testing in Clinical Laboratories.</article-title>
            <source>Cancers (Basel)</source>
            <year>2022</year>
            <month>Jul</month>
            <day>28</day>
            <volume>14</volume>
            <issue>15</issue>
            <pub-id pub-id-type="pmid">35954349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hammond</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Almeida</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Mamotte</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schollaardt</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Angel</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Neurath</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Giulivi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koultchitski</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rachlis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Neifer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lalonde</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Roger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jeanneau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mallal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>External quality assessment of HLA-B*5701 reporting: an international multicentre survey.</article-title>
            <source>Antivir Ther</source>
            <year>2007</year>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>1027</fpage>
            <page-range>1027-32</page-range>
            <pub-id pub-id-type="pmid">18018760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ananthula</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Venna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kumar Polumuri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mattson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Cardone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boyd</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Natarajan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abdoulaeva</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Roderiquez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hildebrand</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Beaucage</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Margulies</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Norcross</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated Peptides.</article-title>
            <source>Front Immunol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>629399</fpage>
            <pub-id pub-id-type="pmid">33633747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monshi</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Faulkner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Earnshaw</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Alfirevic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cederbrant</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pirmohamed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Naisbitt</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury.</article-title>
            <source>Hepatology</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>727</fpage>
            <page-range>727-39</page-range>
            <pub-id pub-id-type="pmid">22987284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Migueles</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Sabbaghian</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Shupert</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Bettinotti</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Marincola</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Martino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hallahan</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Selig</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2000</year>
            <month>Mar</month>
            <day>14</day>
            <volume>97</volume>
            <issue>6</issue>
            <fpage>2709</fpage>
            <page-range>2709-14</page-range>
            <pub-id pub-id-type="pmid">10694578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kroetz</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Abacavir pharmacogenetics--from initial reports to standard of care.</article-title>
            <source>Pharmacotherapy</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>765</fpage>
            <page-range>765-75</page-range>
            <pub-id pub-id-type="pmid">23649914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saag</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Balu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brachman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Martorell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Burman</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stancil</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mosteller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brothers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wannamaker</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sutherland-Phillips</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mallal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shaefer</surname>
                <given-names>M</given-names>
              </name>
              <collab>Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team</collab>
            </person-group>
            <article-title>High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.</article-title>
            <source>Clin Infect Dis</source>
            <year>2008</year>
            <month>Apr</month>
            <day>01</day>
            <volume>46</volume>
            <issue>7</issue>
            <fpage>1111</fpage>
            <page-range>1111-8</page-range>
            <pub-id pub-id-type="pmid">18444831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phillips</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Mallal</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B*57:01 peptide repertoire alteration.</article-title>
            <source>J Clin Invest</source>
            <year>2018</year>
            <month>Jul</month>
            <day>02</day>
            <volume>128</volume>
            <issue>7</issue>
            <fpage>2746</fpage>
            <page-range>2746-2749</page-range>
            <pub-id pub-id-type="pmid">29781810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cardone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tilahun</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Boyd</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Gebreyohannes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roderiquez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Akue</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Juengst</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mattson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ananthula</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Natarajan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Puig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Margulies</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Norcross</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity.</article-title>
            <source>J Clin Invest</source>
            <year>2018</year>
            <month>Jul</month>
            <day>02</day>
            <volume>128</volume>
            <issue>7</issue>
            <fpage>2819</fpage>
            <page-range>2819-2832</page-range>
            <pub-id pub-id-type="pmid">29782330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hughes</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Foisy</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Dewhurst</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Lechelt</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Abacavir hypersensitivity reaction: an update.</article-title>
            <source>Ann Pharmacother</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>387</fpage>
            <page-range>387-96</page-range>
            <pub-id pub-id-type="pmid">18303141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barbarino</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kroetz</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>PharmGKB summary: abacavir pathway.</article-title>
            <source>Pharmacogenet Genomics</source>
            <year>2014</year>
            <month>May</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>276</fpage>
            <page-range>276-82</page-range>
            <pub-id pub-id-type="pmid">24625462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-562.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Norcross</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boyne</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Gomarteli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rennels</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Woodcock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Margulies</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>McMurtrey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vernon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hildebrand</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Buchli</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity.</article-title>
            <source>AIDS</source>
            <year>2012</year>
            <month>Jul</month>
            <day>17</day>
            <volume>26</volume>
            <issue>11</issue>
            <fpage>F21</fpage>
            <page-range>F21-9</page-range>
            <pub-id pub-id-type="pmid">22617051</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
